NCT05901818View on ClinicalTrials.gov

Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Parkinson's Disease
Interventions
DRUG

Autologous induced neural stem cell-derived DA precursor cells

The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.

Trial Locations (1)

100053

RECRUITING

Xuanwu Hospital Capital Medical University, Beijing

All Listed Sponsors
lead

Xuanwu Hospital, Beijing

OTHER